Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022 | Press Releases

CUPERTINO, Calif., May 17, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 16, 2022 | Press Releases

– Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie Citrome, MD & Larry Ereshefsky, PharmD – Topline data for pivotal Phase 3 trial evaluating...

Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

May 3, 2022 | Press Releases

CUPERTINO, Calif., May 03, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

Apr 26, 2022 | Press Releases

Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, 2022 — Reviva Pharmaceuticals Holdings, Inc....

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Mar 24, 2022 | Press Releases

CUPERTINO, Calif., March 24, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...